All News
Filter News
Found 12,610 articles
-
In a study conducted by researchers at Stanford University, three pediatric patients with a rare genetic disease that often results in kidney failure received kidney transplants.
-
The model has been validated against clinically relevant IBD therapies to demonstrate efficacy and mechanism of action, enabling drug developers to gain more accurate therapeutic insights.
-
INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT
6/16/2022
Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy for solid tumors.
-
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
6/16/2022
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat) targeting carcinoma catabolism.
-
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
6/16/2022
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613® (devimistat) targeting carcinoma catabolism.
-
BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer
6/16/2022
Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 career launches, including specific expertise in hematopoietic stem cell mobilization.
-
Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting
6/16/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have a poster presentation at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, to be held June 15-18, 2022 in San Francisco, California.
-
MorphoSys is having a busy week after entering into an equity participation agreement with HIBio and a supply agreement and clinical collaboration with Pfizer and Incyte.
-
Black/African American hematological cancer patients tend to have the worst outcomes. This is partly driven by a lack of access to allogeneic hematopoietic stem cell transplant and available donors.
-
Fecal Transplants Appear Crucial to Protecting Newborns After Receiving Antibiotics
6/15/2022
Antibiotics are among the most powerful superheroes of medicine. From the introduction of penicillin in the 1930s to the dramatic rescues that occur when doctors use strong antibiotics like vancomycin to combat "superbugs," many people know that bacteria-slaying antibiotics have saved uncounted lives from deadly infections.
-
Omeros Announces Webcast Details for Annual Meeting of Shareholders
6/15/2022
Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022, starting at 10:00 a.m. Pacific Time.
-
Cord Blood Banking Services Market is Estimated to Cross US$ 64.7 Mn By 2027, Increase in incidence of Genetic Disorders to Drive the Market
6/15/2022
Wilmington, Delaware, United States: Transparency Market Research has published a new report titled, ‘Cord Blood Banking Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
-
MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.
-
AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer
6/14/2022
AVM Biotechnology, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovative Research (SBIR) grant.
-
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
6/14/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), announced today that the companies entered into an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody.
-
Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine
6/14/2022
Codagenix Inc. today announced that it has completed dosing of its Phase 1 clinical trial to evaluate CodaVax™-H1N1, a universal, live-attenuated influenza vaccine.
-
Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases
6/14/2022
Propanc Biopharma, Inc. announced that the Company’s lead product candidate, PRP, targets solid tumors, which accounts for 80 – 90% of cancer cases, according to the National Cancer Institute.
-
Philip A. Okala Joins City of Hope as System President
6/14/2022
City of Hope, one of the largest cancer research and treatment organizations in the United States, announced that Philip Okala, chief operating officer at the University of Pennsylvania Health System, will join the organization as system president.
-
Urinary Catheter Market Size 2022-2030: Increasing Urinary Incontinence Among Women Due to Childbirth, Menopause, And Others
6/14/2022
Advancements in the healthcare sector have introduced modern medical devices that have revolutionized medical treatments, which improved the quality of life of people suffering from lifestyle and chronic diseases
-
Cancer Biomarkers Market Demand 2022-2030: Rise in Number of Cancer Patients Has Led to Rise in Investments from Government to Establish Specialized Hospitals
6/14/2022
The global cancer biomarker market size is expected to reach USD 118.08 Billion in 2030 and register a revenue CAGR of 17.6% over the forecast period, according to the latest report by Reports and Data.